

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov) and include 508 Accommodation and the title of the document in the subject line of your e-mail.

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use KYMRIA® safely and effectively. See full prescribing information for KYMRIA®.

KYMRIA® (tisagenlecleucel) suspension for intravenous infusion  
Initial U.S. Approval: 2017

### WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES

*See full prescribing information for complete boxed warning.*

- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIA®. Do not administer KYMRIA® to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. (2.3, 2.4, 5.1)
- Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIA®, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIA®. Provide supportive care as needed. (5.2)
- T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIA®. (5.8)

### RECENT MAJOR CHANGES

Boxed Warning	6/2025
Dosage and Administration (2.3)	6/2025
Warnings and Precautions (5.1, 5.2)	6/2025
Warnings and Precautions, KYMRIA® REMS (5.3)	Removed 6/2025
Warnings and Precautions, Effects on Ability to Drive and Use Machines (5.10)	Removed 6/2025

### INDICATIONS AND USAGE

KYMRIA® is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of:

- Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. (1.1)
- Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.  
Limitations of Use: KYMRIA® is not indicated for treatment of patients with primary central nervous system lymphoma. (1.2)
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). (1.3)

### DOSAGE AND ADMINISTRATION

**For autologous use only. For intravenous use only.**

- Administer a lymphodepleting regimen if needed before infusion of KYMRIA®. (2.3)
- Do NOT use a leukodepleting filter. (2.3)
- Verify the patient's identity prior to infusion. (2.3)
- Premedicate with acetaminophen and an H1-antihistamine. (2.3)
- Confirm availability of tocilizumab prior to infusion. (2.3, 5.1)
- Dosing of KYMRIA® is based on the number of chimeric antigen receptor (CAR)-positive viable T cells.
- **Pediatric and Young Adult B-cell ALL (up to 25 years of age)**
  - For patients 50 kg or less, administer 0.2 to 5.0 x 10<sup>6</sup> CAR-positive viable T cells per kg body weight intravenously. (2.1)

- For patients above 50 kg, administer 0.1 to 2.5 x 10<sup>8</sup> total CAR-positive viable T cells (non-weight based) intravenously. (2.1)
- **Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma**
  - Administer 0.6 to 6.0 x 10<sup>8</sup> CAR-positive viable T cells intravenously. (2.2)

### DOSAGE FORMS AND STRENGTHS

- **Pediatric and Young Adult B-cell ALL (up to 25 years of age)**

A single dose of KYMRIA® contains 0.2 to 5.0 x 10<sup>6</sup> CAR-positive viable T cells per kg of body weight for patients 50 kg or less, or 0.1 to 2.5 x 10<sup>8</sup> CAR-positive viable T cells for patients more than 50 kg, suspended in one to three patient-specific infusion bag(s) for intravenous infusion. (3)

- **Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma**

A single dose of KYMRIA® contains 0.6 to 6.0 x 10<sup>8</sup> CAR-positive viable T cells suspended in one to three patient-specific infusion bag(s) for intravenous infusion. (3)

### CONTRAINDICATIONS

None. (4)

### WARNINGS AND PRECAUTIONS

- **Hypersensitivity Reactions:** Monitor for hypersensitivity reactions during infusion. (5.4)
- **Serious Infections:** Monitor patients for signs and symptoms of infection; treat appropriately. (5.5)
- **Prolonged Cytopenias:** Patients may exhibit ≥ Grade 3 cytopenias for several weeks following KYMRIA® infusion. Prolonged neutropenia has been associated with increased risk of infection. (5.6)
- **Hypogammaglobulinemia:** Monitor and provide replacement therapy until resolution. Assess immunoglobulin levels in newborns of mothers treated with KYMRIA®. (5.7)
- **Secondary Malignancies:** T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including KYMRIA®. In the event that a secondary malignancy occurs after treatment with KYMRIA®, contact Novartis Pharmaceuticals Corporation at 1-844-4KYMRIA®. (5.8)

### ADVERSE REACTIONS

**Pediatric and Young Adult B-cell ALL (up to 25 years of age):** The most common adverse reactions (incidence greater than 20%) are CRS, infections-pathogen unspecified, hypogammaglobulinemia, fever, decreased appetite, viral infectious disorders, headache, febrile neutropenia, hemorrhage, musculoskeletal pain, vomiting, encephalopathy, diarrhea, hypotension, cough, nausea, bacterial infectious disorders, pain, hypoxia, tachycardia, edema, fatigue, and acute kidney injury. (6.1)

**Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma:** The most common adverse reactions (incidence greater than 20%) are CRS, infections-pathogen unspecified, fever, diarrhea, nausea, fatigue, hypotension, edema, hemorrhage, dyspnea, and headache. (6.1)

**Adult Relapsed or Refractory Follicular Lymphoma:** The most common adverse reactions (incidence greater than 20%) are CRS, infections-pathogens unspecified, fatigue, musculoskeletal pain, headache, and diarrhea. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.**

**Revised: 6/2025**

---

**FULL PRESCRIBING INFORMATION: CONTENTS\*****WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES****1 INDICATIONS AND USAGE**

- 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma
- 1.3 Adult Relapsed or Refractory Follicular Lymphoma

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Dosage in Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- 2.2 Dosage in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma
- 2.3 Administration
- 2.4 Management of Severe Adverse Reactions

**3 DOSAGE FORMS AND STRENGTHS****4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

- 5.1 Cytokine Release Syndrome
- 5.2 Neurological Toxicities
- 5.3 Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
- 5.4 Hypersensitivity Reactions
- 5.5 Serious Infections
- 5.6 Prolonged Cytopenias
- 5.7 Hypogammaglobulinemia
- 5.8 Secondary Malignancies

**6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience
- 6.3 Immunogenicity

**7 DRUG INTERACTIONS****8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

**11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics/Cellular Kinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES**

- 14.1 Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- 14.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma
- 14.3 Adult Relapsed or Refractory Follicular Lymphoma

**15 REFERENCES****16 HOW SUPPLIED/STORAGE AND HANDLING****17 PATIENT COUNSELING INFORMATION**

\*Sections or subsections omitted from the full prescribing information are not listed.

---

## FULL PRESCRIBING INFORMATION

### **WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES**

- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see *Dosage and Administration* (2.3, 2.4), *Warnings and Precautions* (5.1)].
- Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care as needed [see *Warnings and Precautions* (5.2)].
- T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIAH [see *Warnings and Precautions* (5.8)].

## **1 INDICATIONS AND USAGE**

KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

### **1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia**

Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

### **1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma**

Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.

### **1.3 Adult Relapsed or Refractory Follicular Lymphoma**

Adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and duration of response [see *Clinical Studies* (14.3)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

## **2 DOSAGE AND ADMINISTRATION**

**For autologous use only. For intravenous use only.**

### **2.1 Dosage in Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia**

KYMRIAH is provided as a single-dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive viable T cells.

Based on the patient weight reported at the time of leukapheresis:

- Patients 50 kg or less: administer  $0.2$  to  $5.0 \times 10^6$  CAR-positive viable T cells per kg body weight.
- Patients above 50 kg: administer  $0.1$  to  $2.5 \times 10^8$  CAR-positive viable T cells.

### **2.2 Dosage in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma**

KYMRIAH is provided as a single-dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive viable T cells.

- For adult patients: administer  $0.6$  to  $6.0 \times 10^8$  CAR-positive viable T cells.

## 2.3 Administration

### Preparing Patient for KYMRIA® Administration with Lymphodepletion

- Confirm availability of KYMRIA® prior to starting the lymphodepleting regimen.

### Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

- Lymphodepleting chemotherapy: Fludarabine (30 mg/m<sup>2</sup> intravenously daily for 4 days) and cyclophosphamide (500 mg/m<sup>2</sup> intravenously daily for 2 days starting with the first dose of fludarabine).
- Infuse KYMRIA® 2 to 14 days after completion of the lymphodepleting chemotherapy.

### Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma and r/r Follicular Lymphoma

- Lymphodepleting chemotherapy: Fludarabine (25 mg/m<sup>2</sup> intravenously daily for 3 days) and cyclophosphamide (250 mg/m<sup>2</sup> intravenously daily for 3 days starting with the first dose of fludarabine).
- Alternate lymphodepleting chemotherapy: bendamustine 90 mg/m<sup>2</sup> intravenously daily for 2 days if a patient experienced a previous Grade 4 hemorrhagic cystitis with cyclophosphamide or demonstrates resistance to a previous cyclophosphamide containing regimen.
- Infuse KYMRIA® 2 to 11 days (r/r DLBCL) or 2 to 6 days (r/r FL) after completion of the lymphodepleting chemotherapy.
- Lymphodepleting chemotherapy may be omitted if a patient is experiencing significant cytopenia, e.g., white blood cell (WBC) count is less than 1 x 10<sup>9</sup>/L within 1 week prior to KYMRIA® infusion.

### Preparation of KYMRIA® for Infusion and Administration

Delay the infusion of KYMRIA® if a patient has unresolved serious adverse reactions (including pulmonary reactions, cardiac reactions, or hypotension) from preceding chemotherapies, active uncontrolled infection, active graft versus host disease (GVHD), or worsening of leukemia burden following lymphodepleting chemotherapy [*see Warnings and Precautions (5.1)*].


A KYMRIA® dose may be contained in one to three cryopreserved patient specific infusion bag(s). Verify the number of bags received for the dose of KYMRIA® with the Certificate of Conformance (CoC) and Certificate of Analysis (CoA). Coordinate the timing of thaw of KYMRIA® and infusion in the following manner. Confirm the infusion time in advance, and adjust the start time for thaw so that KYMRIA® is available for infusion when the recipient is ready. If more than one bag has been received for the treatment dose, thaw 1 bag at a time. Wait to thaw/infuse the next bag until it is determined that the previous bag is safely administered.

#### *Preparation of KYMRIA® for Infusion*

1. Confirm tocilizumab and emergency equipment are available prior to infusion and during the recovery period.
2. Premedicate patient with acetaminophen and diphenhydramine or another H1-antihistamine approximately 30 to 60 minutes prior to KYMRIA® infusion. Avoid prophylactic use of systemic corticosteroids, as it may interfere with the activity of KYMRIA®.
3. Confirm patient identity: Prior to KYMRIA® preparation, match the patient's identity with the patient identifiers on each KYMRIA® infusion bag(s). KYMRIA® is for autologous use only. Employ universal precautions to avoid potential transmission of infectious diseases when handling the product.

Note: The patient identifier number may be preceded by the letters DIN or Aph ID.

**Figure 1. KYMRIA® Infusion Bag**



4. Inspect the infusion bag(s) for any breaks or cracks prior to thawing. If a bag is compromised, do not infuse the contents. Call Novartis at 1-844-4KYMRIA®.
5. Place the infusion bag inside a second, sterile bag in case of a leak and to protect ports from contamination.
6. Thaw each infusion bag one at a time at 37°C using either a water bath or dry thaw method until there is no visible ice in the infusion bag. Remove bag from thawing device immediately; do not store product bag at 37°C. Once the infusion bag has been thawed and is at room temperature (20°C to 25°C), it should be infused within 30 minutes. Do not wash, spin down, and/or resuspend KYMRIA® in new media prior to infusion.
7. Inspect the contents of the thawed infusion bag for any visible cell clumps. If visible cell clumps remain, gently mix the contents of the bag. Small clumps of cellular material should disperse with gentle manual mixing. Do not infuse KYMRIA® if clumps are not dispersed, the infusion bag is damaged or leaking, or otherwise appears to be compromised. Call Novartis at 1-844-4KYMRIA®.

#### *Administration*

8. Confirm the patient's identity with the patient identifiers on the infusion bag.
9. Administer KYMRIA® as an intravenous infusion at 10 mL to 20 mL per minute, adjusted as appropriate for smaller children and smaller volumes. The volume in the infusion bag ranges from 10 mL to 50 mL. Do NOT use a leukocyte-depleting filter. If more than one bag is being infused for the treatment dose, wait to thaw/infuse the next bag until it is determined that the previous bag is safely administered.
  - Prime the tubing prior to infusion with sodium chloride 9 mg/mL (0.9%) solution for injection.
  - Infuse all contents of the infusion bag.
  - Rinse the infusion bag with 10 mL to 30 mL sodium chloride 9 mg/mL (0.9%) solution for injection while maintaining a closed tubing system to assure as many cells as possible are infused into the patient.
  - Cells from all the bag(s) must be infused to complete a single dose.

KYMRIA® contains human cells genetically modified with a lentivirus. Follow local biosafety guidelines applicable for handling and disposal of such products.

#### *Monitoring*

- Monitor patients daily during the first week following KYMRIA® infusion for signs and symptoms of CRS and neurologic toxicities [see *Warnings and Precautions* (5.1, 5.2)].
- Instruct patients to remain within proximity of a healthcare facility for at least 2 weeks following infusion.

- Advise patients to avoid driving for at least 2 weeks following infusion.

## 2.4 Management of Severe Adverse Reactions

### *Cytokine Release Syndrome*

Identify CRS based on clinical presentation [see *Warnings and Precautions (5.1)*]. Evaluate for and treat other causes of fever, hypoxia, and hypotension. If CRS is suspected, manage according to the recommendations in Table 1 (Lee et al., 2014). Alternative CRS management strategies may be implemented based on appropriate institutional or academic guidelines.

**Table 1. CRS Grading and Management Guidance**

CRS grade <sup>a</sup>	Symptomatic treatment	Tocilizumab	Corticosteroids
<b>Grade 1</b> Mild symptoms requiring symptomatic treatment only (e.g., low grade fever, fatigue, anorexia, etc.)	Exclude other causes (e.g., infection) and treat specific symptoms (e.g., with antipyretics, antiemetics, analgesics, etc.)	In patients with persistent (> 3 days) or refractory fever, consider managing as Grade 2 CRS <sup>b</sup> .	Not applicable
<b>Grade 2</b> Symptoms require and respond to moderate intervention Oxygen requirement < 40% or Hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity	Antipyretics, oxygen, intravenous fluids and/or low dose vasopressors as needed.	Administer tocilizumab <sup>c</sup> intravenously over 1 hour: – 8 mg/kg (max. 800 mg) if body weight ≥ 30 kg – 12 mg/kg if body weight < 30 kg If no improvement after first dose, repeat every 8 hours (limit to a maximum of 3 dosages in 24-hour period; maximum total of 4 doses).	If no improvement within 24 hours of tocilizumab, administer a daily dose of 2 mg/kg/day methylprednisolone intravenously (or equivalent) until vasopressor and oxygen no longer needed, then taper. If not improving, manage as appropriate grade below.
<b>Grade 3</b> Symptoms require and respond to aggressive intervention Oxygen requirement ≥ 40% or Hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis	High-flow oxygen Intravenous fluids, and high-dose or multiple vasopressors Treat other organ toxicities as per local guidelines.	Per Grade 2 If not improving, consider alternative therapy <sup>d</sup> .	Per Grade 2 If not improving, manage as Grade 4.
<b>Grade 4</b> Life-threatening symptoms Requirement for ventilator support or Grade 4 organ toxicity (excluding transaminitis)	Mechanical ventilation Intravenous fluids and high-dose vasopressor(s) Treat other organ toxicities as per local guidelines.	Per Grade 2 If not improving, consider alternative therapy <sup>d</sup> .	Administer methylprednisolone 1,000 mg intravenously one to two times per day for 3 days. If not improving, consider methylprednisolone 1,000 mg intravenously two to three times a day or alternate therapy <sup>d</sup> . Continue corticosteroids until improvement to Grade 1, and then taper as clinically appropriate.

<sup>a</sup>Lee et al., 2014.

<sup>b</sup>Santomasso et al., 2021.

<sup>c</sup>Refer to tocilizumab Prescribing Information for details.

<sup>d</sup>Alternative therapy includes anti-cytokine and anti-T cell therapies as per institutional policy and published guidelines such as (but not limited to) anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG, and ATG.

## Neurologic Toxicities

Patients should be monitored for neurologic toxicities, including ICANS, following KYMRIA<sup>®</sup> infusion, particularly during and after resolution of CRS. Identify neurologic toxicities based on clinical presentation. Evaluate for and treat other causes of neurological symptoms. Consider non-sedating seizure prophylaxis (e.g., levetiracetam) for patients at higher risk of seizure, such as those with seizure history, CNS disease, concerning EEG findings, or neoplastic brain lesions. If neurologic toxicity is suspected, manage according to the recommendations in Table 2. Alternative neurologic toxicities management strategies may be implemented based on appropriate institutional, academic, or consensus guidelines.

**Table 2. Guidance for Grading and Management of ICANS**

ICANS grade <sup>a</sup>	No concurrent CRS	Concurrent CRS
<b>Grade 1</b> ICE score <sup>b</sup> : 7-9 with no depressed level of consciousness	Offer supportive care with intravenous hydration and aspiration precautions.	Administer tocilizumab at any grade CRS, as per dosage recommendation in Table 1. Caution with repeated tocilizumab doses in patients with ICANS. Consider adding corticosteroids to tocilizumab past the first dose <sup>c</sup> .
<b>Grade 2</b> ICE score <sup>b</sup> : 3-6 and/or Mild somnolence awaking to voice	Supportive care as above. Consider dexamethasone 10 mg intravenously every 6-12 hours or methylprednisolone equivalent (1 mg/kg intravenously every 12 hours) until the event is Grade 1 or less. If improving, taper corticosteroids.	Administer tocilizumab at any grade CRS, as per dosage recommendation in Table 1. If refractory to tocilizumab past the first dose, administer dexamethasone 10 mg intravenously every 6-12 hours or methylprednisolone equivalent (1 mg/kg intravenously every 12 hours) until the event is Grade 1 or less, then taper corticosteroids.
<b>Grade 3</b> ICE score <sup>b</sup> : 0-2* and/or Depressed level of consciousness awakening only to tactile stimulus and/or Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention and/or Focal or local edema on neuroimaging	Administer dexamethasone 10 mg intravenously every 6-12 hours or methylprednisolone equivalent (1 mg/kg intravenously every 12 hours).	Administer tocilizumab at any grade CRS, as per dosage recommendation in Table 1. Administer dexamethasone 10 mg intravenously every 6-12 hours or methylprednisolone equivalent (1 mg/kg intravenously every 12 hours). Continue corticosteroids until the event is Grade 1 or less, then taper corticosteroids. If not improving, manage as Grade 4.
<b>Grade 4</b> ICE score <sup>b</sup> : 0* (patient is unarousable and unable to perform ICE) and/or Stupor or coma and/or Life-threatening prolonged seizure (> 5 minutes) or repetitive clinical or electrical seizures without return to baseline in between and/or Diffuse cerebral edema on neuroimaging, decerebrate or decorticate posturing or papilledema, cranial nerve VI palsy, or Cushing's triad	Consider mechanical ventilation for airway protection. Administer high-dose methylprednisolone intravenously 1,000 mg one to two times per day for 3 days. If not improving, consider 1,000 mg of methylprednisolone two to three times per day or alternate therapy <sup>d</sup> . Continue corticosteroids until improvement to Grade 1, and then taper as clinically appropriate. Treat seizures, status epilepticus, and cerebral edema as per institutional guidelines.	Administer tocilizumab at any grade CRS, as per dosage recommendation in Table 1. Administer methylprednisolone 1,000 mg intravenously one to two times per day for 3 days. If not improving, consider methylprednisolone 1,000 mg intravenously two to three times per day or alternate therapy <sup>d</sup> . Continue corticosteroids until improvement to Grade 1, and then taper as clinically appropriate. Treat seizures, status epilepticus, and cerebral edema as per institutional guidelines.

<sup>a</sup>ASTCT criteria for grading NT (Lee et al., 2019); NCI CTCAE criteria for grading NT used in clinical trials.

<sup>b</sup>ICE Assessment Tool: (1) Orientation: orientation to year, month, city, and hospital: 4 points. (2) Naming: ability to name three objects (e.g., point to clock, pen, and button): 3 points. (3) Following commands: ability to follow simple commands (e.g., show me 2 fingers or close your eyes and stick out your tongue): 1 point. (4) Writing: ability to write a standard sentence (e.g., Our national bird is the bald eagle): 1 point. (5) Attention: ability to count backward from 100 by 10: 1 point.

<sup>c</sup>Santomasso et. al., 2021.

<sup>d</sup>Alternate therapy may include anakinra, siltuximab, ruxolitinib, cyclophosphamide, antithymocyte globulin, or intrathecal hydrocortisone (50 mg) plus methotrexate (12 mg).

\*A patient with an ICE score of 0 may be classified as Grade 3 ICANS if awake with global aphasia, but a patient with an ICE score of 0 may be classified as Grade 4 ICANS if unarousable.



### 3 DOSAGE FORMS AND STRENGTHS

**Pediatric and Young Adult r/r B-cell ALL (up to 25 years of age):** A single dose of KYMRIA<sup>®</sup> contains 0.2 to 5.0 x 10<sup>6</sup> CAR-positive viable T cells per kg of body weight for patients 50 kg and below or 0.1 to 2.5 x 10<sup>8</sup> CAR-positive viable T cells for patients above 50 kg, suspended in one to three patient-specific infusion bag(s) [see *How Supplied/Storage and Handling* (16)].

**Adult r/r DLBCL and r/r FL:** A single dose of KYMRIA<sup>®</sup> contains 0.6 to 6.0 x 10<sup>8</sup> CAR-positive viable T cells, which may be suspended in one to three patient-specific infusion bag(s) [see *How Supplied/Storage and Handling* (16)].

See the CoA for actual cell count. The volume in the infusion bag ranges from 10 mL to 50 mL.

### 4 CONTRAINDICATIONS

None.

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Cytokine Release Syndrome

CRS, including fatal or life-threatening reactions, occurred following treatment with KYMRIA<sup>®</sup>. CRS occurred in 61 (77%) of the 79 pediatric and young adult patients with r/r ALL receiving KYMRIA<sup>®</sup>, including ≥ Grade 3 CRS (Penn grading system<sup>1</sup>) occurring in 48% of patients. The median times to onset and resolution of CRS were 3 days (range, 1 to 22; 1 patient with onset after Day 10) and 8 days (range, 1 to 36), respectively. Of the 61 patients with CRS, 31 (51%) received tocilizumab. Ten (16%) patients received two doses of tocilizumab and 3 (5%) patients received three doses of tocilizumab; 17 (28%) patients received addition of corticosteroids (e.g., methylprednisolone).

CRS occurred in 85 (74%) of the 115 adult patients with r/r DLBCL receiving KYMRIA<sup>®</sup>, including ≥ Grade 3 CRS (Penn grading system<sup>1</sup>) occurring in 23% of patients. The median times to onset and resolution of CRS were 3 days (range, 1 to 51; 1 patient with onset after Day 10) and 7 days (range, 2 to 30), respectively. Of the 85 patients with CRS, 19 (22%) received systemic tocilizumab or corticosteroids. Seven (8%) patients received a single dose of tocilizumab and 11 (13%) patients received two doses of tocilizumab; 11 (13%) patients received corticosteroids in addition to tocilizumab. One patient received corticosteroids for CRS without concomitant tocilizumab, and two patients received corticosteroids for persistent neurotoxicity after resolution of CRS.

CRS occurred in 51 (53%) of the 97 adult patients with r/r FL receiving KYMRIA<sup>®</sup>; all were Grade 1 or 2 CRS (Lee grading system<sup>2</sup>). The median times to onset and resolution of CRS were 4 days (range, 1 to 14) and 4 days (range, 1 to 13), respectively. Of the 51 patients with CRS, 15 (29%) received systemic anticytokine treatment with tocilizumab. Three (6%) patients required 3 dosages of tocilizumab, 4 (8%) patients required 2 dosages and 8 (16%) patients required single dose of tocilizumab. Two (4%) patients received corticosteroids in addition to tocilizumab.

Five deaths occurred within 30 days of KYMRIA<sup>®</sup> infusion. One patient with r/r ALL died with CRS and progressive leukemia, and one patient had resolving CRS with abdominal compartment syndrome, coagulopathy, and renal failure when an intracranial hemorrhage occurred. Of the 3 r/r DLBCL patients who died within 30 days of infusion, all had CRS in the setting of stable to progressive underlying disease, one of whom developed bowel necrosis.

Among patients with CRS, key manifestations include fever (93% in r/r ALL; 85% in r/r DLBCL; 92% in r/r FL), hypotension (69% in r/r ALL; 45% in r/r DLBCL; 40% in r/r FL), hypoxia (57% in r/r ALL; 35% in r/r DLBCL; 19% in r/r FL), and tachycardia (26% in r/r ALL; 13% in r/r DLBCL; 2% in r/r FL). CRS may be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy.

Delay the infusion of KYMRIA<sup>®</sup> after lymphodepleting chemotherapy if the patient has unresolved serious adverse reactions from preceding chemotherapies (including pulmonary toxicity, cardiac toxicity, or hypotension), active uncontrolled infection, active graft versus host disease (GVHD), or worsening of leukemia burden [see *Dosage and Administration* (2.3)].

Risk factors for severe CRS in the pediatric and young adult r/r B-cell ALL population are high pre-infusion tumor burden (greater than 50% blasts in bone marrow), uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy, active infections, and/or inflammatory processes.

Confirm that a minimum of two doses of tocilizumab are available on site prior to infusion of KYMRIA<sup>®</sup>.

Monitor patients daily during the first week following KYMRIA<sup>®</sup> infusion for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 2 weeks after treatment with KYMRIA<sup>®</sup>. At the first sign of CRS,

immediately evaluate patient for hospitalization and institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated [see *Dosage and Administration* (2.3, 2.4)].

Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time [see *Patient Counseling Information* (17)].

## **5.2 Neurological Toxicities**

Neurological toxicities, including severe or life-threatening reactions, occurred following treatment with KYMRIA. Neurologic toxicities occurred in 56 (71%) of the 79 patients with r/r ALL, including  $\geq$  Grade 3 in 22%. The median times to the first event and duration were 6 days from infusion (range, 1 to 301) and 7 days, respectively.

Neurologic toxicities occurred in 69 (60%) of the 115 patients with r/r DLBCL, including  $\geq$  Grade 3 in 19%. The median times to the first event and duration were 5 days (range, 1 to 368) and 17 days, respectively.

Neurologic toxicities occurred in 42 (43%) of the 97 patients with r/r FL, including  $\geq$  Grade 3 in 6%. The median times to the first event and duration were 8 days (range, 1 to 345) and 5 days, respectively.

Among patients who had a neurological toxicity, 84% occurred within 8 weeks following KYMRIA infusion. Resolution occurred within 3 weeks in 71% of patients with r/r ALL, 50% of patients with r/r DLBCL, and 74% of patients with r/r FL. Encephalopathy lasting up to 70 days was noted.

The onset of neurological toxicity can be concurrent with CRS, following resolution of CRS or in the absence of CRS.

The most common neurological toxicities observed with KYMRIA include headache (35% in r/r ALL; 21% in r/r DLBCL; 25% in r/r FL), encephalopathy (30% in r/r ALL; 16% in r/r DLBCL; 3% in r/r FL), delirium (19% in r/r ALL; 5% in r/r DLBCL; 1% in r/r FL), anxiety (16% in r/r ALL; 10% in r/r DLBCL; 2% in r/r FL), sleep disorders (11% in r/r ALL; 10% in r/r DLBCL; 6% in r/r FL), dizziness (5% in r/r ALL; 12% in r/r DLBCL; 8% in r/r FL), tremor (8% in r/r ALL; 6% in r/r DLBCL; 3% in r/r FL), and peripheral neuropathy (4% in r/r ALL; 12% in r/r DLBCL; 7% in r/r FL). Other manifestations included seizures and aphasia.

Monitor patients daily during the first week following KYMRIA infusion for signs and symptoms of neurologic toxicities. Rule out other causes of neurological symptoms. Monitor patients for signs or symptoms of neurologic toxicities for at least 2 weeks after infusion and treat promptly. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed [see *Dosage and Administration* (2.3)]. Advise patients to avoid driving for at least 2 weeks following infusion.

Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity occur at any time [see *Patient Counseling Information* (17)].

## **5.3 Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome**

Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS), which can be life-threatening or fatal, has occurred following treatment with KYMRIA. HLH was reported in 6% (5/79) of patients with r/r ALL (time to onset ranged from 3 to 18 days) and 2% (2/115) of patients with r/r DLBCL (times to onset were Day 7 and Day 10); all HLH events occurred during ongoing CRS and resolved. One patient (1%) with r/r FL developed HLH > 1 year after receiving KYMRIA with a fatal outcome. The patient did not have CRS during or immediately preceding HLH. Treatment of HLH should be administered as per institutional standards.

## **5.4 Hypersensitivity Reactions**

Allergic reactions may occur with infusion of KYMRIA. Serious hypersensitivity reactions, including anaphylaxis, may be due to the DMSO or dextran 40 in KYMRIA. Observe patients for hypersensitivity reactions during the infusion.

## **5.5 Serious Infections**

Infections, including life-threatening or fatal infections, occurred following treatment with KYMRIA. Infections occurred in 57 (72%) of the 79 patients with r/r ALL; 38 patients (48%) experienced  $\geq$  Grade 3 infections, including fatal infections in 2 patients (3%).

Infections occurred in 67 (58%) of the 115 patients with r/r DLBCL; 38 patients (33%) experienced  $\geq$  Grade 3 infections, including fatal infection in 1 patient (1%).

Infections occurred in 50 (52%) of the 97 patients with r/r FL; 20 patients (21%) experienced  $\geq$  Grade 3 infections, including fatal infection in 1 patient (1%).

Prior to KYMRIA<sup>®</sup> infusion, infection prophylaxis should follow local guidelines. Patients with active uncontrolled infection should not start KYMRIA<sup>®</sup> treatment until the infection is resolved. Monitor patients for signs and symptoms of infection after treatment with KYMRIA<sup>®</sup> and treat appropriately [see *Dosage and Administration* (2.3)].

Febrile neutropenia ( $\geq$  Grade 3) was also observed in 34% of patients with r/r ALL, 17% of patients with r/r DLBCL, and 13% of patients with r/r FL after KYMRIA<sup>®</sup> infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids and other supportive care as medically indicated.

#### *Viral Reactivation*

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs directed against B cells.

There is no experience with manufacturing KYMRIA<sup>®</sup> for patients with a positive test for HIV or with active HBV or active HCV. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

### **5.6 Prolonged Cytopenias**

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and KYMRIA<sup>®</sup> infusion.

In the ELIANA study (Study 1),  $\geq$  Grade 3 cytopenias not resolved by Day 28 following KYMRIA<sup>®</sup> treatment included neutropenia (40%), and thrombocytopenia (27%) among 52 responding patients. At 56 days following KYMRIA<sup>®</sup>, 17% and 12% of responding patients had  $\geq$  Grade 3 neutropenia or thrombocytopenia, respectively.

In the JULIET study (Study 2),  $\geq$  Grade 3 cytopenias not resolved by Day 28 following KYMRIA<sup>®</sup> treatment included thrombocytopenia (39%) and neutropenia (25%) among 115 treated patients.

In the ELARA study (Study 3),  $\geq$  Grade 3 cytopenias not resolved by Day 28 following KYMRIA<sup>®</sup> treatment included thrombocytopenia (17%) and neutropenia (16%) among 97 treated patients.

Prolonged neutropenia has been associated with increased risk of infection. Myeloid growth factors, particularly GM-CSF, are not recommended during the first 3 weeks after KYMRIA<sup>®</sup> infusion or until CRS has resolved.

### **5.7 Hypogammaglobulinemia**

Hypogammaglobulinemia and agammaglobulinemia related to B-cell aplasia can occur in patients after KYMRIA<sup>®</sup> infusion.

Hypogammaglobulinemia was reported in 53% of patients treated with KYMRIA<sup>®</sup> for r/r ALL, 17% of patients with r/r DLBCL, and 18% of patients with r/r FL [see *Clinical Pharmacology* (12.3)].

Monitor immunoglobulin levels after treatment with KYMRIA<sup>®</sup> and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement standard guidelines.

#### *Immunization with Live Vaccine*

The safety of immunization with live vaccines during or following KYMRIA<sup>®</sup> treatment has not been studied. Vaccination with live vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during KYMRIA<sup>®</sup> treatment, and until immune recovery following treatment with KYMRIA<sup>®</sup>.

Pregnant women who have received KYMRIA<sup>®</sup> may have hypogammaglobulinemia. Assess immunoglobulin levels in newborns of mothers treated with KYMRIA<sup>®</sup>.

### **5.8 Secondary Malignancies**

Patients treated with KYMRIA<sup>®</sup> may develop secondary malignancies or recurrence of their cancer. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIA<sup>®</sup>. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes [see *Boxed Warning, Adverse Reactions* (6.2), *Patient Counseling Information* (17)].

Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Novartis Pharmaceuticals Corporation at 1-844-4KYMRIA<sup>®</sup> to obtain instructions on patient samples to collect for testing.

## 6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in another section of the label:

- Cytokine Release Syndrome [*see Warnings and Precautions (5.1)*]
- Neurological Toxicities [*see Warnings and Precautions (5.2)*]
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome [*see Warnings and Precautions (5.3)*]
- Serious Infections [*see Warnings and Precautions (5.5)*]
- Prolonged Cytopenias [*see Warnings and Precautions (5.6)*]
- Hypogammaglobulinemia [*see Warnings and Precautions (5.7)*]

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in the WARNINGS AND PRECAUTIONS and in this section reflect exposure to KYMRIAH in three non-randomized, single-arm studies in which 79 pediatric and young adult patients with relapsed/refractory (r/r) B-cell ALL (ELIANA Study), 115 adults with r/r diffuse large B-cell lymphoma (JULIET Study), and 97 adults with r/r follicular lymphoma (ELARA Study) received a single dose of CAR-positive viable T cells.

#### *Pediatric and Young Adult r/r B-cell Acute Lymphoblastic Leukemia (ALL) (up to 25 years of age)*

Based on a recommended dose which was weight-based, all 79 patients in the ELIANA study (Study 1) received a single intravenous dose of KYMRIAH [*see Clinical Studies (14.1)*]. The most common adverse reactions (> 20%) were CRS (77%), infections-pathogen unspecified (57%), hypogammaglobulinemia (53%), fever (42%), decreased appetite (38%), viral infectious disorders (38%), headache (35%), febrile neutropenia (34%), hemorrhage (32%), musculoskeletal pain (32%), vomiting (32%), encephalopathy (30%), bacterial infectious disorders (29%), diarrhea (29%), hypotension (29%), cough (27%), nausea (27%), pain (25%), hypoxia (25%), tachycardia (24%), edema (23%), fatigue (23%), and acute kidney injury (22%).

The adverse reactions with greater than or equal to 10% incidence for any Grade are summarized in Table 3.

**Table 3. Selected Adverse Reactions Anytime After Infusion (≥ 10%) Following Treatment with KYMRIA<sup>®</sup> in Pediatric and Young Adult r/r B-cell ALL (N = 79)**

Adverse reaction	All Grades (%)	Grades 3 or higher (%)
<i>Blood and lymphatic system disorders</i>		
Febrile neutropenia	34	34
<i>Cardiac disorders</i>		
Tachycardia <sup>a</sup>	24	4
<i>Gastrointestinal disorders</i>		
Vomiting	32	1
Diarrhea	29	1
Nausea	27	3
Abdominal pain <sup>b</sup>	18	3
Constipation	18	0
<i>General disorders and administration site conditions</i>		
Fever	42	13
Pain <sup>c</sup>	25	3
Fatigue <sup>d</sup>	23	0
Edema <sup>e</sup>	23	8
<i>Immune system disorders</i>		
Cytokine release syndrome	77	48
Hypogammaglobulinemia <sup>f</sup>	53	13
<i>Infections and infestations</i>		
Infections-pathogen unspecified	57	27
Viral infectious disorders	37	22
Bacterial infectious disorders	29	16
Fungal infectious disorders	15	9
<i>Metabolism and nutrition disorders</i>		
Decreased appetite	38	15
Hypocalcemia	20	6
Hyperferritinemia <sup>g</sup>	10	3
<i>Musculoskeletal and connective tissue disorders</i>		
Musculoskeletal pain <sup>h</sup>	32	4
Arthralgia	14	1
<i>Nervous system disorders</i>		
Headache <sup>i</sup>	35	3
Encephalopathy <sup>j</sup>	30	9
<i>Psychiatric disorders</i>		
Delirium <sup>k</sup>	19	4
Anxiety	17	3
Sleep disorder <sup>l</sup>	11	0
<i>Renal and urinary disorders</i>		
Acute kidney injury <sup>m</sup>	22	14
<i>Respiratory, thoracic and mediastinal disorders</i>		
Cough <sup>n</sup>	27	0
Hypoxia	25	20
Dyspnea <sup>o</sup>	19	14
Pulmonary edema	15	9
Nasal congestion	11	0
Oropharyngeal pain	10	0
Pleural effusion	10	4
Tachypnea	10	5
<i>Skin and subcutaneous tissue disorders</i>		
Rash <sup>p</sup>	18	1
<i>Vascular disorders</i>		
Hemorrhage <sup>q</sup>	32	10
Hypotension	29	20
Hypertension	19	5

---

<sup>a</sup>Tachycardia includes sinus tachycardia and tachycardia.

<sup>b</sup>Abdominal pain includes abdominal pain, abdominal pain upper.

<sup>c</sup>Pain includes pain and pain in extremity.

<sup>d</sup>Fatigue includes fatigue and malaise.

<sup>e</sup>Edema includes face edema, fluid overload, generalized edema, localized edema, edema peripheral.

<sup>f</sup>Hypogammaglobulinemia includes hypogammaglobulinemia, immunoglobulins decreased, blood immunoglobulin G decreased, blood immunoglobulin A decreased, blood immunoglobulin M decreased, immunodeficiency, immunodeficiency common variable.

<sup>g</sup>Hyperferritinemia includes serum ferritin increased.

<sup>h</sup>Musculoskeletal pain includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and non-cardiac chest pain.

<sup>i</sup>Headache includes headache and migraine.

<sup>j</sup>Encephalopathy includes encephalopathy, cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, lethargy, mental status changes, somnolence, memory impairment, and automatism. Encephalopathy is a dominant feature of immune effector cell-associated neurotoxicity syndrome (ICANS), along with other symptoms.

<sup>k</sup>Delirium includes delirium, agitation, hallucination, hallucination visual, irritability, restlessness.

<sup>l</sup>Sleep disorder includes sleep disorder, insomnia and nightmare.

<sup>m</sup>Acute kidney injury includes acute kidney injury, anuria, azotemia, renal failure, renal tubular dysfunction, renal tubular necrosis, and blood creatinine increased.

<sup>n</sup>Cough includes cough and productive cough.

<sup>o</sup>Dyspnea includes acute respiratory failure, dyspnea, respiratory distress, and respiratory failure.

<sup>p</sup>Rash includes dermatitis, rash, rash maculo-papular, rash papular, and rash pruritic.

<sup>q</sup>Hemorrhage includes anal hemorrhage, catheter site hemorrhage, cerebral hemorrhage, conjunctival hemorrhage, contusion, cystitis hemorrhagic, disseminated intravascular coagulation, epistaxis, gastrointestinal hemorrhage, gingival bleeding, hemarthrosis, hematemesis, hematuria, hemoptysis, heavy menstrual bleeding, melena, mouth hemorrhage, peritoneal hematoma, petechiae, pharyngeal hemorrhage, purpura, retinal hemorrhage, vaginal hemorrhage.

Additional important adverse reactions that did not meet the threshold criteria for inclusion in Table 3 were:

*Blood and lymphatic system disorders:* coagulopathy (6%), hemophagocytic lymphohistiocytosis (6%), pancytopenia (3%)

*Cardiac disorders:* cardiac failure<sup>a</sup> (9%), arrhythmia<sup>b</sup> (4%)

*Eye disorders:* visual impairment (3%)

*Gastrointestinal disorders:* abdominal distention (4%), ascites (4%), stomatitis (4%), abdominal compartment syndrome (1%), dry mouth (1%)

*General disorders and administration site conditions:* chills (9%), asthenia (4%), influenza-like illness (3%), multiple organ dysfunction syndrome (3%)

*Immune system disorders:* infusion related reaction (6%), graft versus host disease (3%)

*Investigations:* prothrombin time prolonged (4%), fibrin D dimer increased (3%), weight decreased (3%)

*Metabolism and nutrition disorders:* tumor lysis syndrome (6%), hypercalcemia (4%)

*Nervous system disorders:* tremor (8%), seizure<sup>c</sup> (6%), dizziness (5%), peripheral neuropathy<sup>d</sup> (4%), speech disorder<sup>e</sup> (3%), motor dysfunction<sup>f</sup> (1%), neuralgia (1%)

*Respiratory, thoracic, and mediastinal disorders:* acute respiratory distress syndrome (4%), lung infiltration (1%)

*Skin and subcutaneous tissue disorders:* pruritus (9%), erythema (6%), hyperhidrosis (4%), night sweats (1%)

*Vascular disorders:* capillary leak syndrome (3%), thrombosis (3%), flushing (1%)

---

<sup>a</sup>Cardiac failure includes cardiac failure, cardiac failure congestive, left ventricular dysfunction, right ventricular dysfunction.

<sup>b</sup>Arrhythmia includes cardiac arrest.

<sup>c</sup>Seizure includes generalized tonic-clonic seizure and seizure.

<sup>d</sup>Peripheral neuropathy includes hyperesthesia, hypoesthesia, paresthesia.

<sup>e</sup>Speech disorder includes aphasia and dysarthria.

<sup>f</sup>Motor dysfunction includes muscle spasms.

## Laboratory Abnormalities

**Table 4. Grade 3 or 4 Laboratory Abnormalities Occurring in > 10% of Patients Following Treatment with KYMRIAH in Pediatric and Young Adult r/r B-cell ALL based on CTCAE<sup>a</sup> (N = 79)**

Laboratory abnormality	Grade 3 or 4 (%)
<b>Hematology</b>	
Blood fibrinogen decreased	11
<b>Biochemistry</b>	
Aspartate aminotransferase increased	29
Hypokalemia	28
Alanine aminotransferase increased	22
Hypophosphatemia	20
Hyperbilirubinemia	19
Hyperglycemia	13

<sup>a</sup>CTCAE = Common Terminology Criteria for Adverse Events version 4.03.

All patients experienced neutropenia, anemia and thrombocytopenia. See Table 5 for the incidences of  $\geq$  Grade 3 prolonged thrombocytopenia and prolonged neutropenia in responding patients.

**Table 5. Prolonged Cytopenias Following Treatment with KYMRIAH in Pediatric and Young Adult r/r B-cell ALL**

Prolonged cytopenia	N = 52 (%)	N = 52 (%)
	Day 28	Day 56
Prolonged neutropenia <sup>a</sup>	40	17
Prolonged thrombocytopenia <sup>a</sup>	27	12

<sup>a</sup> $\geq$  Grade 3 observed within 14 days after Day 28 or Day 56 in responding patients.

### *Adult r/r Diffuse Large B-cell Lymphoma (DLBCL)*

In the JULIET study (Study 2) 115 adults with r/r DLBCL received a single intravenous dose of KYMRIAH [see *Clinical Studies (14.2)*]. The most common adverse reactions (incidence > 20%) were CRS, infections-pathogen unspecified, fever, diarrhea, nausea, fatigue, hypotension, edema, bleeding episodes, dyspnea, and headache.

The study population characteristics were median age of 56 years (range, 22 to 76 years), 80% DLBCL; a median of 3 prior lines of therapy (range, 1 to 6), 49% had a prior autologous hematopoietic stem cell transplantation, and 32% had received prior radiation therapy. One hundred seven patients (93%) received lymphodepleting chemotherapy prior to KYMRIAH, which included fludarabine (n = 85) or bendamustine (n = 22).

The adverse reactions with greater than or equal to 10% incidence for any Grade are summarized in Table 6 below.

**Table 6. Selected Adverse Reactions Anytime After Infusion Reported in  $\geq 10\%$  Following Treatment with KYMRIAH in Adult r/r DLBCL (N = 115)**

<b>Adverse reaction</b>	<b>All Grades (%)</b>	<b>Grades 3 or higher (%)</b>
<i>Blood and lymphatic system disorders</i>		
Febrile neutropenia	17	17
<i>Cardiac disorders</i>		
Tachycardia <sup>a</sup>	13	3
Arrhythmia <sup>b</sup>	10	5
<i>Gastrointestinal disorders</i>		
Diarrhea	31	1
Nausea	29	1
Constipation	17	1
Abdominal pain <sup>c</sup>	10	2
<i>General disorders and administration site conditions</i>		
Fever	35	5
Fatigue <sup>d</sup>	27	6
Edema <sup>e</sup>	27	3
Pain <sup>f</sup>	14	3
Chills	12	0
<i>Immune system disorders</i>		
Cytokine release syndrome	74	23
Hypogammaglobulinemia <sup>g</sup>	17	6
<i>Infections and infestations</i>		
Infections-pathogen unspecified	48	26
Bacterial infectious disorders	17	8
Fungal infectious disorders	11	5
Viral infectious disorders	11	2
<i>Investigations</i>		
Weight decreased	12	4
<i>Metabolism and nutrition disorders</i>		
Decreased appetite	14	4
<i>Musculoskeletal and connective tissue disorders</i>		
Arthralgia	14	0
Musculoskeletal pain <sup>h</sup>	13	1
<i>Nervous system disorders</i>		
Headache <sup>i</sup>	21	1
Encephalopathy <sup>j</sup>	16	11
Peripheral neuropathy <sup>k</sup>	12	3
Dizziness <sup>l</sup>	12	2
<i>Psychiatric disorders</i>		
Anxiety	10	1
Sleep disorder <sup>m</sup>	10	0
<i>Renal and urinary disorders</i>		
Acute kidney injury <sup>n</sup>	17	6
<i>Respiratory, thoracic and mediastinal disorders</i>		
Dyspnea <sup>o</sup>	21	6
Cough <sup>p</sup>	17	0
<i>Skin and subcutaneous tissue disorders</i>		
Rash <sup>q</sup>	11	0
<i>Vascular disorders</i>		
Hypotension <sup>r</sup>	25	9
Hemorrhage <sup>s</sup>	22	8



---

<sup>a</sup>Tachycardia includes sinus tachycardia and tachycardia.

<sup>b</sup>Arrhythmia includes atrial fibrillation, cardiac arrest, supraventricular tachycardia, and ventricular extrasystoles.

<sup>c</sup>Abdominal pain includes abdominal discomfort, abdominal pain, and abdominal pain upper.

<sup>d</sup>Fatigue includes fatigue and malaise.

<sup>e</sup>Edema includes face edema, fluid overload, fluid retention, generalized edema, localized edema, edema peripheral, peripheral swelling.

<sup>f</sup>Pain includes pain and pain in extremity.

<sup>g</sup>Hypogammaglobulinemia includes blood immunoglobulin G decreased, immunodeficiency, immunoglobulins decreased and hypogammaglobulinemia.

<sup>h</sup>Musculoskeletal pain includes back pain, flank pain, musculoskeletal chest pain, neck pain, and non-cardiac chest pain.

<sup>i</sup>Headache includes headache and migraine.

<sup>j</sup>Encephalopathy includes cognitive disorder, confusional state, disturbance in attention, lethargy, mental status changes, somnolence, memory impairment, metabolic encephalopathy and thinking abnormal. Encephalopathy is a dominant feature of immune effector cell-associated neurotoxicity syndrome (ICANS), along with other symptoms.

<sup>k</sup>Peripheral neuropathy includes paraesthesia, hypoaesthesia, hyperaesthesia, peripheral sensory neuropathy, neuropathy peripheral, cranial nerve paralysis, demyelinating polyneuropathy, Horner's syndrome, polyneuropathy, and sciatica.

<sup>l</sup>Dizziness includes dizziness, presyncope, and syncope.

<sup>m</sup>Sleep disorder includes insomnia and sleep disorder.

<sup>n</sup>Acute kidney injury includes acute kidney injury, blood creatinine abnormal, and blood creatinine increased.

<sup>o</sup>Dyspnea includes dyspnea, dyspnea exertional, respiratory distress, and respiratory failure.

<sup>p</sup>Cough includes cough, productive cough, and upper-airway cough syndrome.

<sup>q</sup>Rash includes dermatitis, dermatitis acneiform, dermatitis contact, rash, rash maculo-papular, rash papular, and rash pruritic.

<sup>r</sup>Hypotension includes hypotension and orthostatic hypotension.

<sup>s</sup>Hemorrhage includes anal hemorrhage, blood urine present, cerebral hemorrhage, contusion, cystitis hemorrhagic, disseminated intravascular coagulation, duodenal ulcer hemorrhage, epistaxis, eye contusion, gastrointestinal hemorrhage, hematemesis, hematochezia, hematuria, large intestinal hemorrhage, melena, mouth hemorrhage, petechiae, pharyngeal hemorrhage, post procedural hemorrhage, pulmonary hemorrhage, purpura, retinal hemorrhage, traumatic hematoma, tumor hemorrhage, upper gastrointestinal hemorrhage.

Additional important adverse reactions that did not meet the threshold criteria for inclusion in Table 5 were:

*Blood and lymphatic system disorders:* pancytopenia (3%), hemophagocytic lymphohistiocytosis (2%), B-cell aplasia (1%)

*Cardiac disorders:* cardiac failure<sup>a</sup> (1%)

*Eye disorders:* visual impairment<sup>b</sup> (6%)

*Gastrointestinal disorders:* vomiting (9%), stomatitis (6%), dry mouth (5%), abdominal distension (4%), ascites (3%)

*General disorders and administration site conditions:* influenza-like illness (9%), asthenia (7%), multiple organ dysfunction syndrome (3%)

*Immune system disorders:* infusion related reaction (3%)

*Investigations:* fibrin D dimer increased (4%)

*Metabolism and nutrition disorders:* hypocalcemia (5%), hypercalcemia (4%), hyperferritinemia<sup>c</sup> (4%), tumor lysis syndrome (2%)

*Musculoskeletal and connective tissue disorders:* myalgia (5%)

*Nervous system disorders:* motor dysfunction<sup>d</sup> (6%), tremor<sup>e</sup> (6%), speech disorder<sup>f</sup> (4%), neuralgia<sup>g</sup> (3%), seizure<sup>h</sup> (3%), ataxia<sup>i</sup> (2%), ischemic cerebral infarction (1%)

*Psychiatric disorders:* delirium<sup>j</sup> (5%)

*Respiratory, thoracic, and mediastinal disorders:* hypoxia (8%), oropharyngeal pain<sup>k</sup> (8%), pleural effusion (5%), nasal congestion (4%), pulmonary edema<sup>l</sup> (3%), tachypnea (3%)

*Skin and subcutaneous tissue disorders:* night sweats (5%), pruritus (4%), hyperhidrosis (4%), erythema (2%)

*Vascular disorders:* thrombosis<sup>m</sup> (6%), hypertension (4%), capillary leak syndrome (1%)

---

<sup>a</sup>Cardiac failure includes cardiac failure congestive.

<sup>b</sup>Visual impairment includes vision blurred and visual impairment.

<sup>c</sup>Hyperferritinemia includes serum ferritin increased.

<sup>d</sup>Motor dysfunction includes muscle spasms, muscle twitching, myoclonus and myopathy.

<sup>e</sup>Tremor includes dyskinesia and tremor.

<sup>f</sup>Speech disorder includes speech disorder, aphasia, and dysarthria.

<sup>g</sup>Neuralgia includes neuralgia and sciatica.

<sup>h</sup>Seizure includes PTs seizure and status epilepticus.

<sup>i</sup>Ataxia includes ataxia and dysmetria.

<sup>j</sup>Delirium includes delirium, agitation, and irritability.

<sup>k</sup>Oropharyngeal pain includes oral pain and oropharyngeal pain.

<sup>l</sup>Pulmonary edema includes acute pulmonary edema and pulmonary edema.

<sup>m</sup>Thrombosis includes deep vein thrombosis, embolism, pulmonary embolism, thrombosis, vena cava thrombosis, and venous thrombosis.

## Laboratory Abnormalities

**Table 7. Grade 3 or 4 Laboratory Abnormalities Occurring in > 10% of Patients Following KYMRIA<sup>®</sup> Infusion in Adult r/r DLBCL Patients Based on CTCAE<sup>a</sup> N = 115**

Laboratory parameter	Grade 3 or 4 (%)
<b>Hematology</b>	
Lymphopenia	95
Neutropenia	82
Leukopenia	78
Anemia	59
Thrombocytopenia	56
<b>Biochemistry</b>	
Hypophosphatemia	24
Hypokalemia	13

<sup>a</sup>CTCAE = Common Terminology Criteria for Adverse Events version 4.03.

### Adult r/r Follicular Lymphoma (FL)

The safety of KYMRIA<sup>®</sup> was evaluated in the ELARA study (Study 3), a trial that included 97 patients with r/r FL who received a single intravenous dose of KYMRIA<sup>®</sup> [see *Clinical Studies* (14.3)]. Patients with a history of CNS disorders or autoimmune disease requiring systemic immunosuppression were ineligible. The median age was 57 years (range, 29 to 73 years), 34% were female, 75% were White, 13% were Asian, and 1% were Black or African American.

The most common adverse reactions (incidence > 20%) were CRS, infections-pathogen unspecified, fatigue, musculoskeletal pain, headache, and diarrhea.

The adverse reactions with greater than or equal to 10% incidence for any Grade are summarized in Table 8 below.

**Table 8. Selected Adverse Reactions Anytime After Infusion Reported in ≥ 10% Following Treatment with KYMRIA<sup>®</sup> in Adult r/r FL (N = 97)**

Adverse reaction	All Grades (%)	Grades 3 or higher (%)
<i>Blood and lymphatic system disorders</i>		
Febrile neutropenia	13	13
<i>Gastrointestinal disorders</i>		
Diarrhea	24	2
Nausea	16	2
Constipation	16	0
Abdominal pain <sup>a</sup>	10	1
<i>General disorders and administration site conditions</i>		
Fatigue <sup>b</sup>	27	3
Fever	19	1
<i>Immune system disorders</i>		
Cytokine release syndrome	53	0
Hypogammaglobulinemia <sup>c</sup>	18	1
<i>Infections and infestations</i>		
Infections-pathogen unspecified	38	12
Viral infectious disorders	18	5
<i>Musculoskeletal and connective tissue disorders</i>		
Musculoskeletal pain <sup>d</sup>	25	1
Arthralgia	10	0
<i>Nervous system disorders</i>		
Headache <sup>e</sup>	25	2
<i>Respiratory, thoracic and mediastinal disorders</i>		
Cough <sup>f</sup>	19	0

Adverse reaction	All Grades (%)	Grades 3 or higher (%)
<i>Skin and subcutaneous tissue disorders</i>		
Rash <sup>g</sup>	10	0

<sup>a</sup>Abdominal pain includes abdominal pain and abdominal pain upper.

<sup>b</sup>Fatigue includes asthenia, fatigue, and malaise.

<sup>c</sup>Hypogammaglobulinemia includes blood immunoglobulin G decreased and hypogammaglobulinemia.

<sup>d</sup>Musculoskeletal pain includes back pain, bone pain, flank pain, muscle discomfort, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and non-cardiac chest pain.

<sup>e</sup>Headache includes headache and migraine.

<sup>f</sup>Cough includes cough and productive cough.

<sup>g</sup>Rash includes rash, rash maculo-papular, and rash papular.

Additional important adverse reactions that did not meet the threshold criteria for inclusion in Table 8 were:

*Blood and lymphatic system disorders:* pancytopenia (3%), hemolysis<sup>a</sup> (2%), coagulopathy<sup>b</sup> (2%)

*Cardiac disorders:* tachycardia<sup>c</sup> (2%), arrhythmia<sup>d</sup> (4%)

*Eye disorders:* visual impairment<sup>e</sup> (4%)

*Gastrointestinal disorders:* vomiting (9%), stomatitis<sup>f</sup> (4%), abdominal distension (2%), dry mouth (2%)

*General disorders and administration site conditions:* edema<sup>g</sup> (9%), pain<sup>h</sup> (8%), chills (6%)

*Immune system disorders:* infusion related reaction (3%), graft versus host disease<sup>i</sup> (1%), hemophagocytic lymphohistiocytosis (1%)

*Infections and infestations:* bacterial infectious disorders (7%), fungal infectious disorders (2%)

*Investigations:* weight decreased (7%)

*Metabolism and nutrition disorders:* decreased appetite (8%), tumor lysis syndrome (2%)

*Nervous system disorders:* dizziness<sup>j</sup> (8%), motor dysfunction<sup>k</sup> (9%), peripheral neuropathy<sup>l</sup> (7%), immune effector cell-associated neurotoxicity syndrome (4%), encephalopathy (3%), tremor (3%)

*Psychiatric disorders:* sleep disorder<sup>m</sup> (6%), anxiety (2%), delirium (1%)

*Renal and urinary disorder:* acute kidney injury<sup>n</sup> (4%)

*Respiratory, thoracic, and mediastinal disorders:* dyspnea<sup>o</sup> (8%), pleural effusion (6%), oropharyngeal pain (5%), nasal congestion (2%), rhinorrhea (2%)

*Skin and subcutaneous tissue disorders:* pruritus (9%), night sweats (3%), erythema (2%), hyperhidrosis (1%)

*Vascular disorders:* hypotension<sup>p</sup> (9%), hemorrhage<sup>q</sup> (6%), hypertension (5%), thrombosis<sup>r</sup> (1%)

<sup>a</sup>Hemolysis includes hemolysis and hemolytic anemia.

<sup>b</sup>Coagulopathy includes coagulopathy and international normalized ratio increased.

<sup>c</sup>Tachycardia includes sinus tachycardia.

<sup>d</sup>Arrhythmia includes atrial fibrillation, atrioventricular block first degree, and electrocardiogram QT prolonged.

<sup>e</sup>Visual impairment includes blindness (preexisting progressive blindness, which initiated prior to start of lymphodepleting chemotherapy, further worsened after KYMRIAH infusion), vision blurred, and visual impairment.

<sup>f</sup>Stomatitis includes mouth ulceration and stomatitis.

<sup>g</sup>Edema includes edema peripheral, fluid retention, hypervolemia, localized edema, and peripheral swelling.

<sup>h</sup>Pain includes ear pain, pain, and pain in extremity.

<sup>i</sup>Graft versus host disease includes graft versus host disease in gastrointestinal tract and graft versus host disease in skin.

<sup>j</sup>Dizziness includes dizziness and syncope.

<sup>k</sup>Motor dysfunction includes dyskinesia, muscle spasms, muscular weakness, musculoskeletal stiffness, and myoclonus.

<sup>l</sup>Peripheral neuropathy includes dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, and peripheral sensory neuropathy.

<sup>m</sup>Sleep disorder includes insomnia.

<sup>n</sup>Acute kidney injury includes acute kidney injury and blood creatinine increased.

<sup>o</sup>Dyspnea includes acute respiratory failure, dyspnea, and dyspnea exertional.

<sup>p</sup>Hypotension includes hypotension and orthostatic hypotension.

<sup>q</sup>Hemorrhage includes blood blister, catheter site hemorrhage, contusion, epistaxis, hematochezia, hematoma, mucosal hemorrhage, oral blood blister, petechiae, and purpura.

<sup>r</sup>Thrombosis includes deep vein thrombosis.

## Laboratory Abnormalities

**Table 9. Grade 3 or 4 Laboratory Abnormalities Occurring in > 10% of Patients Following KYMRIA<sup>®</sup> Infusion in Adult r/r FL Patients Based on CTCAE<sup>a</sup> (N = 97\*)**

Laboratory abnormality	Grade 3 or 4 (%)
<b>Hematology</b>	
Neutropenia	63
Leukopenia	40
Thrombocytopenia	21
Anemia	20
Lymphopenia	19
<b>Biochemistry</b>	
Hypophosphatemia	12

<sup>a</sup>CTCAE = Common Terminology Criteria for Adverse Events version 4.03.

\*Evaluable population (n = 91 to 97) for each laboratory value included number of patients who had both baseline (before KYMRIA<sup>®</sup> infusion) and at least one post-KYMRIA<sup>®</sup> infusion on-study laboratory value available.

## **6.2 Postmarketing Experience**

Because adverse events to marketed products are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure.

The following adverse events have been identified during postmarketing use of KYMRIA<sup>®</sup>.

- Anaphylactic reaction
- Neoplasms: T cell malignancies

## **6.3 Immunogenicity**

In clinical studies, humoral immunogenicity of KYMRIA<sup>®</sup> was measured by determination of anti-murine CAR19 antibodies (anti-mCAR19) in serum pre- and post-administration. The majority of patients, 91% in ELIANA (Study 1), 94% in JULIET (Study 2), and 66% in ELARA (Study 3), tested positive for pre-dose anti-mCAR19 antibodies prior to KYMRIA<sup>®</sup> infusion. Treatment induced anti-mCAR19 antibodies were detected in 9% and 33% of the patients in JULIET and ELARA, respectively. However, the preexisting and treatment-induced antibodies were not associated with an impact on clinical response and did not have an impact on the initial expansion and persistence of KYMRIA<sup>®</sup>. Persistence of KYMRIA<sup>®</sup> was similar between patients with positive post-infusion anti-mCAR19 antibodies compared with patients with negative post-infusion anti-mCAR19 antibodies. There is no evidence that the presence of preexisting and treatment-induced anti-mCAR19 antibodies impact the safety or effectiveness of KYMRIA<sup>®</sup>.

T cell immunogenicity responses were not observed in r/r ALL, r/r DLBCL, or r/r FL patients.

## **7 DRUG INTERACTIONS**

HIV and the lentivirus used to make KYMRIA<sup>®</sup> have limited, short spans of identical genetic material (RNA). Therefore, some commercial HIV nucleic acid tests (NATs) may yield false-positive results in patients who have received KYMRIA<sup>®</sup>.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

There are no available data with KYMRIA<sup>®</sup> use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with KYMRIA<sup>®</sup> to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known if KYMRIA<sup>®</sup> has the potential to be transferred to the fetus. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia. Therefore, KYMRIA<sup>®</sup> is not recommended for women who are pregnant, and pregnancy after KYMRIA<sup>®</sup> administration should be discussed with the treating physician. Report pregnancies to Novartis Pharmaceuticals Corporation at 1-888-669-6682.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

## **8.2 Lactation**

### Risk Summary

There is no information regarding the presence of KYMRIA<sup>®</sup> in human milk, the effect on the breastfed infant, and the effects on milk production. A risk to the breastfed infant cannot be excluded. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KYMRIA<sup>®</sup> and any potential adverse effects on the breastfed infant from KYMRIA<sup>®</sup> or from the underlying maternal condition.

## **8.3 Females and Males of Reproductive Potential**

### Pregnancy Testing

Pregnancy status of females with reproductive potential should be verified. Sexually-active females of reproductive potential should have a pregnancy test prior to starting treatment with KYMRIA<sup>®</sup>.

### Contraception

See the prescribing information for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy.

There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with KYMRIA<sup>®</sup>.

### Infertility

There are no data on the effect of KYMRIA<sup>®</sup> on male and female fertility.

## **8.4 Pediatric Use**

The safety and efficacy of KYMRIA<sup>®</sup> have been established in pediatric patients with r/r B-cell ALL. Use of KYMRIA<sup>®</sup> is supported by a single-arm trial [*see Clinical Studies (14.1)*] that included 61 pediatric patients with r/r B-cell precursor ALL in the following age groups: 40 children (ages 2 years to less than 12 years) and 21 adolescents (ages 12 years to less than 17 years). No differences in efficacy or safety were observed between the different age subgroups or in comparison to the young adults in the trial.

The safety and efficacy of KYMRIA<sup>®</sup> in pediatric patients with r/r DLBCL and r/r FL have not been established.

## **8.5 Geriatric Use**

The safety and effectiveness of KYMRIA<sup>®</sup> have not been established in geriatric patients with r/r B-cell ALL. Clinical studies of KYMRIA<sup>®</sup> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

## **11 DESCRIPTION**

KYMRIA<sup>®</sup> (tisagenlecleucel) is a CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells that are genetically modified using a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains for 4-1BB (CD137) and CD3 zeta.

KYMRIA<sup>®</sup> is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure. The mononuclear cells are enriched for T cells, then transduced with the lentiviral vector containing the anti-CD19 CAR transgene and activated with anti-CD3/CD28 antibody coated beads. The transduced T cells are expanded in cell culture, washed, and formulated into a suspension, which then is cryopreserved. The product must pass a sterility test before release for shipping as a frozen suspension in a patient-specific infusion bag(s). The product is thawed prior to administration [*see Dosage and Administration (2.3), How Supplied/Storage and Handling (16)*]. The thawed product is a colorless to slightly yellow suspension of cells.

In addition to T cells, other cell populations, including monocytes, NK cells, and B cells, may be present. The formulation contains 31.25% (v/v) of Plasma-Lyte A, 31.25% (v/v) of 5% Dextrose/0.45% sodium chloride, 10% Dextran 40 (LMD)/5% Dextrose, 20% (v/v) of 25% Human Serum Albumin (HSA), and 7.5% (v/v) Cryoserv<sup>®</sup> dimethyl sulfoxide (DMSO).

**Pediatric and Young Adult r/r B-cell ALL:** A single dose of KYMRIAHA may contain up to  $2.5 \times 10^8$  CAR-positive viable T cells provided in one to three patient-specific infusion bag(s). Based on the patient's weight reported at the time of leukapheresis, one of two possible dose ranges will be prepared for the patient:

- For patients 50 kg or less:  $0.2$  to  $5.0 \times 10^6$  CAR-positive viable T cells per kg body weight.
- For patients above 50 kg:  $0.1$  to  $2.5 \times 10^8$  CAR-positive viable T cells.

**Adult r/r DLBCL and r/r FL:** A single dose of KYMRIAHA may contain  $0.6$  to  $6.0 \times 10^8$  CAR-positive viable T cells provided in one to three patient-specific infusion bag(s).

The actual number of CAR-positive T cells in the product is reported on the Certificate of Analysis (CoA) that is shipped with KYMRIAHA. The volume of CAR-positive viable T cells in an infusion bag ranges from 10 mL to 50 mL.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

KYMRIAHA is a CD19-directed genetically modified autologous T cell immunotherapy which involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells. The CAR is comprised of a murine single-chain antibody fragment which recognizes CD19 and is fused to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta. The CD3 zeta component is critical for initiating T cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of KYMRIAHA. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, target cell elimination, and persistence of the KYMRIAHA cells.

### 12.2 Pharmacodynamics

Due to the on-target effect of KYMRIAHA, a period of B-cell aplasia is expected.

Among evaluable pediatric and young adult r/r B-cell ALL patients with an ongoing response at Month 24, 33% had no detectable B cells at baseline prior to infusion. At Month 24, 88% had no detectable B cells.

Most adult r/r DLBCL patients had B-cell depletion at baseline prior to infusion due to previous treatment with rituximab. Recovery of B-cell levels were observed with longer follow-up in some of the responding DLBCL patients after KYMRIAHA infusion. Among evaluable adult r/r DLBCL and FL patients with an ongoing response at Month 24, all patients had no detectable B cells at baseline prior to infusion or at Month 24.

### 12.3 Pharmacokinetics/Cellular Kinetics

Following infusion, KYMRIAHA exhibited an initial rapid expansion followed by a bi-exponential decline in pediatric and young adult r/r B-cell acute lymphoblastic leukemia (ALL) patients, adult r/r diffuse large B-cell lymphoma patients, and adult r/r follicular lymphoma patients.

A summary of pharmacokinetic parameters of KYMRIAHA is provided in Table 10 below.

**Table 10. Pharmacokinetic Parameters of KYMRIAHA in Pediatric and Young Adult r/r B-cell ALL, Adult r/r DLBCL, and Adult r/r FL**

Parameter	Summary statistics	Pediatric ALL responding patients	Pediatric ALL non-responding patients	r/r DLBCL responding patients (CR and PR)	r/r DLBCL non-responding patients (SD/PD/unknown)	r/r FL responding patients (CR and PR)	r/r FL non-responding patients (SD/PD)
		N = 62	N = 8	N = 34	N = 34	N = 77	N = 12
C <sub>max</sub> (copies/mcg)	Geometric mean (CV%), n	34,700 (155.4), 61	20,000 (71.6), 7	5,210 (256.5), 33	6,450 (408.2), 32	6,250 (344), 64	3,000 (1190), 8
T <sub>max</sub> (day)	Median [min; max], n	9.91 [0.008; 27], 61	20.0 [0.03; 62.7], 7	9.83 [5.73; 16.8], 33	8.39 [3.04; 27.7], 32	9.94 [2.62; 28.0], 64	13.0 [7.73; 16.0], 8
AUC <sub>0-28d</sub> (copies/mcg*day)	Geometric mean (CV%), n	318,000 (177.8), 61	156,000 (99.4), 6	58,200 (165.1), 30	75,800 (292.3), 25	56,900 (270), 63	20,100 (18100), 7
T <sub>1/2</sub> (day)	Geometric mean (CV%), n	16.8 (155.9), 54	2.52 (171.9), 3	45.3 (157.7), 21	13.6 (167.0), 22	44.0 (296), 42	24.4 (180), 6

### *Description of Pharmacokinetics in Pediatric and Young Adult r/r B-cell ALL (up to 25 years of age)*

The  $C_{\max}$  and  $AUC_{0-28d}$  were similar between CR/CRi patients compared with non-responding (NR) patients.

KYMRIAH was present in the blood as well as bone marrow and was measurable beyond 2 years. Blood to bone marrow partitioning suggested that KYMRIAH distribution in bone marrow was 44% of that present in blood at Day 28 while at Months 3 and 6 KYMRIAH distributed at 67% and 69%, respectively, indicating high distribution to bone marrow.

Children < 10 years and between 10-18 years of age had similar- to 1.7-fold higher  $C_{\max}$  and  $AUC_{0-28d}$  than adults. Due to small sample size and high variability, it is difficult to assess the impact of age on the pharmacokinetics of KYMRIAH.

### *Description of Pharmacokinetics in Adult r/r DLBCL*

The  $C_{\max}$  and  $AUC_{0-28d}$  were similar between responding and non-responding (NR) patients.

KYMRIAH was present in adult r/r DLBCL patients up to 18 months in peripheral blood and up to 9 months in the bone marrow for patients having a complete response (CR). The median time of maximal expansion of transgene levels ( $T_{\max}$ ) in peripheral blood occurred at 9-10 days in both responding and non-responding patients.

### *Description of Pharmacokinetics in Adult r/r FL*

KYMRIAH has been detected for up to 18 months in peripheral blood and up to 3 months in bone marrow for patients who achieved a response. The median time of maximal expansion of transgene levels ( $T_{\max}$ ) in peripheral blood occurred at 10 days in responding and 13 days in non-responding patients.

The blood to bone marrow partitioning in bone marrow was nearly 50% at Month 3 in responding patients.

The geometric mean  $AUC_{0-28d}$  value of responders was 183% higher compared to non-responders, while the geometric mean  $C_{\max}$  value was 108% higher in responders compared to non-responders. Considering the high inter-individual variability, small number of non-responders, overlapping expansion ranges observed between responders and non-responders, the exposure differences should be interpreted with caution.

### *Tocilizumab and Corticosteroid used for CRS Management*

Some patients required tocilizumab and corticosteroids for the management of CRS. KYMRIAH continues to expand and persist following treatment as per the CRS management algorithm (see Table 1). Patients who have higher expansion tended to have higher CRS Grades [see *Warnings and Precautions (5.1)*].

Pediatric and young adult r/r B-cell ALL patients (N = 28) treated with tocilizumab had 298% and 183% higher KYMRIAH  $AUC_{0-28d}$  and  $C_{\max}$ , respectively, as compared to patients (N = 46) who did not receive tocilizumab. In addition, patients who received corticosteroids for CRS management (N = 17) had 280% higher  $AUC_{0-28d}$  compared with patients who did not receive corticosteroids (N = 31).

Adult r/r DLBCL patients treated with tocilizumab (N = 18) had 238% (n = 14) and 311% (n = 16) higher KYMRIAH  $AUC_{0-28d}$  and  $C_{\max}$ , respectively, as compared to patients (N = 97) who did not receive tocilizumab. In addition, patients who received corticosteroids for CRS management (N = 12) had 104% and 179% higher  $AUC_{0-28d}$  and  $C_{\max}$ , respectively, as compared with patients who did not receive corticosteroids (N = 79).

Adult r/r FL patients treated with tocilizumab (N = 14) had 245% (n = 12) and 312% (n = 11) higher KYMRIAH  $AUC_{0-28d}$  and  $C_{\max}$ , respectively, as compared to patients (N = 76) who did not receive tocilizumab. Three patients received corticosteroids for CRS management while all other patients received corticosteroids for other reasons, therefore a formal comparison for exposure differences by use of corticosteroids cannot be performed.

Hepatic and renal impairment studies of KYMRIAH were not conducted.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Genotoxicity assays and carcinogenicity assessment in rodent models were not performed for KYMRIAH. *In vitro* expansion studies with transduced T cells (KYMRIAH) from healthy donors and patients showed no evidence for transformation and/or immortalization of T cells. *In vivo* studies in immunocompromised mice did not show signs of abnormal cell growth or signs of clonal cell expansion for up to 7 months after cell injection. A genomic insertion site analysis was performed on KYMRIAH products from 14 individual donors (12 patients and 2 healthy volunteers). There

was no evidence for preferential integration near genes of concern, or preferential outgrowth of cells harboring integration sites of concern.

No studies on the effects of KYMRIA<sup>®</sup>H on fertility have been conducted.

14 CLINICAL STUDIES

14.1 Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

The efficacy of KYMRIA<sup>®</sup>H in pediatric and young adults with r/r B-cell precursor ALL was evaluated in an open-label, multicenter single-arm trial (ELIANA, NCT02435849). In total, 107 patients were screened, 88 were enrolled, 68 were treated, and 63 were evaluable for efficacy. Nine percent of the enrolled patients did not receive the product due to manufacturing failure. The 63 evaluable patients included 35 males and 28 females of median age 12 years (range, 3 to 23 years). Seventy-three percent of patients were White, 10% were Asian, and 17% were of other races. Six (10%) had primary refractory disease, 30 (48%) had one prior stem cell transplantation, 5 patients (8%) had two stem cell transplantations. Treatment consisted of lymphodepleting chemotherapy (fludarabine 30 mg/m<sup>2</sup> daily for 4 days and cyclophosphamide 500 mg/m<sup>2</sup> daily for 2 days) followed by a single dose of KYMRIA<sup>®</sup>H. Of the 22 patients who had a WBC count < 1000/μL, 20 received lymphodepleting chemotherapy prior to KYMRIA<sup>®</sup>H while 2 received KYMRIA<sup>®</sup>H infusion without lymphodepleting chemotherapy. Fifty-three patients received bridging chemotherapy between time of enrollment and lymphodepleting chemotherapy.

The efficacy of KYMRIA<sup>®</sup>H was established on the basis of complete remission (CR) within 3 months after infusion, the duration of CR, and proportion of patients with CR and minimal residual disease (MRD) < 0.01% by flow cytometry (MRD-negative) (Table 11). Among the 63 infused patients, 52 (83%) achieved CR/CRi, all of which were MRD-negative. With a median follow-up of 4.8 months from response, the median duration of CR/CRi was not reached (range, 1.2 to 14.1+ months). Median time to onset of CR/CRi was 29 days with onset of CR/CRi between 26 and 31 days for 50/52 (96%) responders. The stem cell transplantation rate among those who achieved CR/CRi was 12% (6/52). Table 11 shows the efficacy results from this study.

Table 11. Efficacy Results in Pediatric and Young Adult Patients with r/r B-cell ALL

Results	N = 63
CR/CRi <sup>1,2</sup> (95% CI)	52 (83%) (71%, 91%) p < 0.0001
CR <sup>3</sup>	40 (63%)
CRi <sup>4</sup>	12 (19%)
CR or CRi with MRD-negative bone marrow <sup>5,6</sup> (95% CI)	52 (83%) (71%, 91%) p < 0.0001
<b>Duration of remission<sup>7</sup></b>	<b>N = 52</b>
Median (months) (95% CI)	Not reached (7.5, NE <sup>8</sup> )

<sup>1</sup>CR/CRi was calculated based on all patients who received KYMRIA<sup>®</sup>H and completed at least 3 months follow-up or discontinued earlier prior to the data cut-off. Requires remission status to be maintained for at least 28 days without clinical evidence of relapse.  
<sup>2</sup>The null hypothesis of CR/CRi less than or equal to 20% was rejected.  
<sup>3</sup>CR (complete remission) was defined as less than 5% of blasts in the bone marrow, no evidence of extramedullary disease, and full recovery of peripheral blood counts (platelets greater than 100,000/microliter and absolute neutrophil counts [ANC] greater than 1,000/microliter) without blood transfusion.  
<sup>4</sup>CRi (complete remission with incomplete blood count recovery) was defined as less than 5% of blasts in the bone marrow, no evidence of extramedullary disease, and without full recovery of peripheral blood counts with or without blood transfusion.  
<sup>5</sup>MRD (minimal residual disease) negative was defined as MRD by flow cytometry less than 0.01%.  
<sup>6</sup>The null hypothesis of MRD-negative remission rate less than or equal to 15% was rejected.  
<sup>7</sup>DOR (duration of remission) was defined as time since onset of CR or CRi to relapse or death due to underlying cancer, whichever is earlier, censoring for new cancer therapy including stem cell transplantation (N = 52).  
<sup>8</sup>Not Estimable.

14.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma

The efficacy and safety of KYMRIA<sup>®</sup>H was evaluated in an open-label, multicenter, single-arm trial (JULIET; NCT02445248). Eligible patients were ≥ 18 years of age with relapsed or refractory DLBCL, who received ≥ 2 lines of chemotherapy, including rituximab and anthracycline, or relapsed following autologous hematopoietic stem cell



transplantation (HSCT). The study excluded patients with active central nervous system malignancy, prior allogeneic HSCT, an ECOG performance status  $\geq 2$ , a creatinine clearance  $< 60$ , alanine aminotransferase  $> 5$  times normal, cardiac ejection fraction  $< 45\%$ , or absolute lymphocyte concentration less than  $300/\mu\text{L}$ .

Following 2 to 11 days after completion of lymphodepleting (LD) chemotherapy consisting of either fludarabine ( $25\text{ mg}/\text{m}^2$  intravenously daily for 3 days) and cyclophosphamide ( $250\text{ mg}/\text{m}^2$  intravenously daily for 3 days starting with the first dose of fludarabine) or bendamustine ( $90\text{ mg}/\text{m}^2$  intravenously daily for 2 days), KYMRIA<sup>®</sup> was administered as a single intravenous infusion. Bridging chemotherapy between leukapheresis and LD chemotherapy was permitted to control disease burden. LD chemotherapy could be omitted if the white blood cell count was  $< 1000\text{ cells}/\mu\text{L}$ . The major efficacy outcome measures were objective response rate per Lugano criteria [2014] as assessed by an independent review committee and duration of response.

Of the 160 patients enrolled, 106 patients received tisagenlecleucel, including 92 patients who received product manufactured in the U.S. and were followed for at least 3 months or discontinued earlier. Eleven out of 160 patients enrolled did not receive tisagenlecleucel due to manufacturing failure. Thirty-eight other patients did not receive tisagenlecleucel, primarily due to death ( $n = 16$ ), physician decision ( $n = 16$ ), and adverse events ( $n = 3$ ).

Of the 92 patients receiving KYMRIA<sup>®</sup>, 90% received physician’s choice of bridging chemotherapy in the interval between start of screening and KYMRIA<sup>®</sup> infusion, among whom the median number of bridging chemotherapy regimens was 1 (range, 1 to 5) with 83% of patients receiving  $\leq 2$  regimens. A retrospectively identified sub-group of 68 patients was evaluable for the major efficacy outcome measures. Patients included in this sub-group had either had no bridging chemotherapy, or had imaging that showed measurable disease after completion of bridging chemotherapy, prior to KYMRIA<sup>®</sup> infusion. Of the 24 patients not included, 8 had no evidence of disease at baseline prior to KYMRIA<sup>®</sup> infusion, 15 did not have baseline imaging following bridging chemotherapy, and 1 was excluded because of initial misclassification of a neuroendocrine tumor as DLBCL.

Among the efficacy evaluable population of 68 patients, the baseline characteristics were median age 56 years (range, 22 to 74 years); 71% male; 90% White, 4% Asian, and 3% Black or African American; 78% had primary DLBCL not otherwise specified (NOS) and 22% had DLBCL following transformation from follicular lymphoma, of whom 17% were identified as high grade; and 44% had undergone prior autologous HSCT. The median number of prior therapies was 3 (range, 1 to 6), 56% had refractory disease and 44% relapsed after their last therapy. Ninety percent of patients received lymphodepleting chemotherapy (66% of patients received fludarabine and 24% received bendamustine) and 10% did not receive any LD chemotherapy. The median time from leukapheresis and cryopreservation to KYMRIA<sup>®</sup> infusion was 113 days (range, 47 to 196 days). The median dose was  $3.5 \times 10^8$  CAR-positive viable T cells (range,  $1.0$  to  $5.2 \times 10^8$  cells). Seventy-three percent of patients received KYMRIA<sup>®</sup> in the inpatient setting.

Efficacy was established on the basis of CR rate and duration of response (DOR), as determined by an independent review committee (Table 12 and Table 13). The median time to first response to KYMRIA<sup>®</sup> (CR or PR) was 0.9 months (range, 0.7 to 3.3 months). The median duration of response was not reached. Response durations were longer in patients who achieved CR, as compared to patients with a best response of partial response (PR) (Table 13). Of the 22 patients who experienced a CR, 9 achieved this status by 1 month, 12 more by month 3, and the last by month 6 after KYMRIA<sup>®</sup> infusion.

**Table 12. Response Rates in Relapsed or Refractory DLBCL in the JULIET Study**

Response rate	N = 68
Overall response rate (ORR) (CR+PR), n (%)	34 (50%)
(95% CI)	(37.6%, 62.4%)
Complete response rate n (%)	22 (32%)
(95% CI)	(21.5%, 44.8%)
Partial response rate n (%)	12 (18%)
(95% CI)	(9.5%, 28.8%)

**Table 13. Duration of Response<sup>a</sup> (Months) in Relapsed or Refractory DLBCL in the JULIET Study**

Duration of response	Results
<b>Overall DOR for responders (months)</b>	<b>N = 34</b>
Median DOR <sup>a,b</sup>	NE
(95% CI)	(5.1, NE)
Range <sup>c</sup>	(0.03+ – 11.3+)
Median Follow-up (95% CI) <sup>b</sup>	9.4 (7.9, 10.8)
<b>DOR if BOR is CR</b>	<b>N = 22</b>
Median DOR <sup>a,b</sup>	NE
(95% CI)	(10.0, NE)
Range <sup>c</sup>	(1.5+ – 11.3+)
<b>DOR if BOR is PR</b>	<b>N = 12</b>
Median DOR <sup>a,b</sup>	3.4
(95% CI)	(1.0, NE)
Range <sup>c</sup>	(0.03+ – 11.3+)

Abbreviations: CR, Complete Response; DOR, Duration of Response; NE, not estimable; PR, partial response.

<sup>a</sup>Among all responders. DOR measured from date of first objective response to date of progression or death from relapse.

<sup>b</sup>Kaplan-Meier estimate in months.

<sup>c</sup>A + sign indicates a censored value.

### 14.3 Adult Relapsed or Refractory Follicular Lymphoma

The efficacy of KYMRIA<sup>®</sup>H was evaluated in a multicenter, single-arm, open-label trial (ELARA, Study 3; NCT03568461) that included patients who were refractory to or relapsed within 6 months after completion of two or more lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent), relapsed during or within six months after completion of an anti-CD20 antibody maintenance therapy following at least two lines of therapy, or relapsed after autologous hematopoietic stem cell transplant (HSCT). The trial excluded patients with active or serious infections, transformed lymphoma, or other aggressive lymphomas, prior allogeneic HSCT, or disease with active CNS involvement. Following lymphodepleting (LD) chemotherapy, KYMRIA<sup>®</sup>H was administered as a single dose intravenous infusion with a target dose of 0.6 to 6.0 × 10<sup>8</sup> CAR-positive viable T cells. The median dose administered was 2.06 × 10<sup>8</sup> CAR-positive viable T-cells (range, 0.1 to 6.0 × 10<sup>8</sup> CAR-positive viable T cells). The LD chemotherapy regimen consisted of either fludarabine (25 mg/m<sup>2</sup> intravenously daily for 3 days) and cyclophosphamide (250 mg/m<sup>2</sup> intravenously daily for 3 days starting with the first dose of fludarabine) or bendamustine (90 mg/m<sup>2</sup> IV daily for 2 days); bridging chemotherapy between leukapheresis and LD chemotherapy was permitted as needed. Of the 90 patients included in the primary efficacy analysis, 40 patients (45%) were treated with bridging therapies. The most commonly used agents (in ≥ 5% of patients) were rituximab (22%), dexamethasone (13%), gemcitabine (12%), prednisone (11%), oxaliplatin (8%), etoposide (8%), and vincristine (6%).

Of 98 patients who were enrolled and underwent leukapheresis, 97 patients received infusion with KYMRIA<sup>®</sup>H and one patient without measurable disease did not receive KYMRIA<sup>®</sup>H. There were no manufacturing failures for the 98 enrolled patients. Of the 97 patients infused with KYMRIA<sup>®</sup>H, the efficacy evaluable population, as specified in the protocol, included the first 90 patients with measurable disease who received KYMRIA<sup>®</sup>H consecutively and had at least 9 months follow-up from first objective response or discontinued earlier.

Among the 90 patients with FL included in the efficacy analysis, the median age was 58 years (range, 29 to 73 years), 31% were female, 78% were White, 10% were Asian, and 1% were Black or African American. The median number of prior therapies was 4 (range, 2 to 13), with 24% receiving 2 prior lines, 21% receiving 3 prior lines, and 54% receiving ≥4 prior lines. Eighty-seven percent had Stage III-IV disease at study entry, 64% had bulky disease, 36% had a prior autologous HSCT, 79% were refractory to the most recent regimen, and 66% had progression within 24 months of initiating their first anti-CD20 combination therapy (POD24).

Efficacy was established on the basis of objective response rate and duration of response (DOR) as determined by an independent review committee (Table 14 and Table 15). The first disease assessment was scheduled to be performed at Month 3 post-infusion; the median time to first response was 2.9 months (range, 0.6 to 6.0 months). All responders achieved their response (complete response [CR] or partial response [PR]) at the first performed post-infusion disease assessment.

**Table 14. Response Rates in Patients with Relapsed or Refractory FL**

Response	Primary efficacy population N = 90	All leukapheresed patients N = 98
Overall response rate (ORR), n (%)	77 (86%)	84 (86%)
(95% CI)	(76.6, 92.1)	(77.2, 92.0)
Complete response rate (CRR) <sup>a,b</sup> , n (%)	61 (68%)	66 (67%)
(95% CI)	(57.1, 77.2)	(57.1, 76.5)

<sup>a</sup>Two patients, included in the Primary Efficacy Population, with best overall response of CR, had their disease relapsed more than 6 months after the last line of therapy.

<sup>b</sup>Of the 30 patients who initially achieved a PR, 14 patients (47%) converted to a CR, including 10 patients at the next subsequent visit and within 6 months post-infusion.

**Table 15. Duration of Response in Patients with Relapsed or Refractory FL**

	From N = 90
<b>Overall DOR, months</b>	N = 77
Median (95% CI) <sup>a,b</sup>	NE (15.6, NE)
Range <sup>c</sup>	(0.03+, 21.1+)
Median Follow-up	9.1*
% event-free probability	
At 9 months (95% CI)	75.2 (63.5, 83.6)
At 12 months (95% CI)	70.8 (58.0, 80.3)
<b>DOR if best response is CR, months</b>	N = 61
Median (95% CI) <sup>a,b</sup>	NE (15.6, NE)
Range <sup>c</sup>	(2.7, 21.1+)
% event-free probability	
At 9 months (95% CI)	87.7 (75.8, 93.9)
At 12 months (95% CI)	85.2 (72.2, 92.4)

Abbreviations: CR, complete response; DOR, duration of response; NE, not estimable.

\*The first disease assessment was scheduled to be performed at Month 3 post-infusion. The median follow up is the time from first objective response to last disease assessment.

<sup>a</sup>Among responders. DOR measured from date of first objective response to date of progression or death from relapse.

<sup>b</sup>Kaplan-Meier estimate in months.

<sup>c</sup>A + sign indicates a censored value.

## 15 REFERENCES

- Porter DL, Hwang WT, Frey N, et al. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Table S4A). *Sci. Transl Med*; 7(303):303ra139. DOI: 10.1126/scitranslmed.aac5415.
- Lee DW, Gardner R, Porter DL, et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*; 124(2):188-95.
- Lee DW, Santomasso BD, Locke FL, et al. (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*; 25(4):625-38.
- Santomasso BD, Nastoupil LJ, Adkins S, et al. (2021) Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. *J Clin Oncol*; 39(35):3978-92.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

KYMRIAH is supplied as a frozen suspension of genetically modified autologous T cells in an infusion bag(s) labeled for the specific recipient. KYMRIAH is shipped directly to the cell lab associated with the infusion center in a liquid nitrogen Dewar. Product and patient-specific labels are located inside the Dewar.

Ped ALL: NDC 0078-0846-19

DLBCL and FL: NDC 0078-0958-19

- Confirm patient identity upon receipt.
- Store infusion bag(s) in a temperature-monitored system less than or equal to minus 120°C, e.g., in the vapor phase of liquid nitrogen.
- Use closed, break-proof, leak-proof containers when transporting infusion bags within the facility.
- Thaw KYMRIAH prior to infusion [*see Dosage and Administration (2)*].

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Ensure that patients understand the risk of manufacturing failure. This has been reported in up to 9% of manufacturing attempts. In case of a manufacturing failure, a second manufacturing of KYMRIAH may be attempted. In addition, while the patient awaits the product, additional chemotherapy (not the lymphodepletion) may be necessary and may increase the risk of adverse events during the pre-infusion period.

Prior to infusion, advise patients of the following risks:

- Cytokine Release Syndrome (CRS) -- Report signs and symptoms of CRS (high fever, difficulty breathing, chills/shaking chills, severe nausea, severe vomiting, severe diarrhea, severe muscle pain, severe joint pain, very low blood pressure, or dizziness/lightheadedness) to their healthcare professional [see *Warnings and Precautions* (5.1), *Adverse Reactions* (6.1)].
- Neurological Toxicities -- Report altered or decreased consciousness, delirium, confusion, agitation, seizures, difficulty speaking and understanding, or loss of balance to their healthcare professional [see *Warnings and Precautions* (5.2), *Adverse Reactions* (6.1)].
- Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) -- Presenting signs and symptoms are similar to those of CRS and infections [see *Warnings and Precautions* (5.3), *Adverse Reactions* (6.1)].
- Serious Infections -- KYMRIAH may cause serious infections. Advise patients that they will be screened for HBV, HCV, and HIV before collection of cells [see *Warnings and Precautions* (5.5), *Adverse Reactions* (6.1)].
- Hypogammaglobulinemia -- Patients may need to receive immunoglobulin replacement for an indefinite amount of time following treatment with KYMRIAH. Patients should tell their physician about their treatment with KYMRIAH before receiving a live vaccine [see *Warnings and Precautions* (5.7), *Adverse Reactions* (6.1)].
- Prolonged Cytopenia -- Patient may exhibit signs or symptoms associated with bone marrow suppression (i.e., neutropenia, thrombocytopenia and anemia) for several weeks following lymphodepleting chemotherapy and KYMRIAH [see *Warnings and Precautions* (5.6)].
- Secondary Malignancies -- Secondary malignancies, including T cell malignancies, have occurred [see *Boxed Warning*, *Warnings and Precautions* (5.8), *Adverse Reactions* (6.2)].

Advise patients of the need to:

- Patients should be instructed to contact Novartis Pharmaceuticals Corporation at 1-844-4KYMRIAH if they get secondary malignancies [see *Warnings and Precautions* (5.8)].
- Avoid driving for at least 2 weeks.

Distributed by:

Novartis Pharmaceuticals Corporation  
East Hanover, New Jersey 07936  
US License Number 1244

© Novartis

**MEDICATION GUIDE**  
**KYMRIAH® (pronounced *KIM-RYE-AH*)**  
**(tisagenlecleucel)**  
**suspension, for intravenous infusion**

Read this Medication Guide before you start your KYMRIAH treatment. The more you know about your treatment, the more active you can be in your care. Talk with your healthcare provider if you have questions about your health condition or treatment. Reading this Medication Guide does not take the place of talking with your healthcare provider about your treatment.

**What is the most important information I should know about KYMRIAH?**

KYMRIAH may cause side effects that are severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following:

- difficulty breathing
- fever (100.4°F/38°C or higher)
- chills/shaking chills
- confusion
- severe nausea, vomiting, diarrhea
- severe muscle or joint pain
- very low blood pressure
- dizziness/lightheadedness

It is important that you tell your healthcare providers that you have received KYMRIAH. Your healthcare providers may give you other medicines to treat your side effects.

**What is KYMRIAH?**

KYMRIAH is made from your own white blood cells and is a prescription cancer treatment used in patients up to 25 years old who have acute lymphoblastic leukemia (ALL) that is either relapsing (went into remission, then came back) or refractory (did not go into remission after receiving other leukemia treatments). It is also used in patients with large B-cell lymphoma or follicular lymphoma, two types of non-Hodgkin lymphoma, that have relapsed or are refractory after having at least two other kinds of treatment.

**How will I get KYMRIAH?**

Since KYMRIAH is made from your own white blood cells, your healthcare provider has to take some of your blood. This is called "leukapheresis." It takes 3 to 6 hours and may need to be repeated. A tube (intravenous catheter) will be placed in your vein to collect your blood.

Your blood cells are frozen and sent to the manufacturing site to make KYMRIAH. It takes about 3-4 weeks from the time your cells are received at the manufacturing site and shipped back to your healthcare provider, but the time may vary.

While waiting for KYMRIAH to be made, your healthcare provider may give you therapy to stabilize your cancer.

In addition, before you get KYMRIAH, your healthcare provider may give you chemotherapy for a few days to prepare your body.

When your body is ready, your healthcare provider will give you KYMRIAH through a tube (intravenous catheter) in your vein. This usually takes less than one hour.

You should plan to stay close to a healthcare facility for at least 2 weeks after getting KYMRIAH. Your healthcare provider will check to see if your treatment is working and help you with any side effects that occur.

**What should I avoid after receiving KYMRIA?**

- Avoid driving for at least 2 weeks after you get KYMRIA.
- Do not donate blood, organs, tissues, sperm, oocytes, and other cells.

**What are the possible or reasonably likely side effects of KYMRIA?****The most common side effects of KYMRIA are:**

- difficulty breathing
- fever (100.4°F/38°C or higher)
- chills/shaking chills
- confusion
- severe nausea, vomiting, diarrhea
- severe muscle or joint pain
- very low blood pressure
- dizziness/lightheadedness
- headache

KYMRIA can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

KYMRIA can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets). After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, are feeling tired, weak, or short of breath, or have bruising or bleeding.

Having KYMRIA in your blood may cause a false-positive HIV test result by some commercial tests.

KYMRIA may increase your risk of getting cancers, including certain types of blood cancers. Your healthcare provider should monitor you for this.

These are not all the possible side effects of KYMRIA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**General information about the safe and effective use of KYMRIA.**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.

Do not use KYMRIA for a condition for which it was not prescribed.

Talk to your healthcare provider about any concerns. You can ask your healthcare provider for information about KYMRIA that is written for healthcare professionals.

Distributed by:

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936.  
US License Number 1244

© Novartis

For more information, go to [KYMRIA.com](http://KYMRIA.com) or call 1-888-669-6682.